帕金森病合并糖尿病的多巴胺能黑质纹状体脆弱性:严重度匹配队列证据
本研究分析两个独立帕金森病(PD)队列(PPMI多中心 n=174,UniBS单中心 n=95),比较合并与不合并糖尿病(DM)患者的基线123I-FP-CIT显像。经年龄、性别和临床严重度匹配后,PD-DM患者黑质纹状体多巴胺摄取相对保留更多,但多巴胺能连接改变更少,左侧壳核神经储备指数降低。提示DM可能与多巴胺系统脆弱性增加相关。
要点
- 未用药PD合并DM者临床严重度相当时多巴胺能丢失更轻。
- 严重度匹配后PD-DM黑质纹状体多巴胺摄取较PD-n更保留。
- PD-DM多巴胺能连接改变更少(10% vs 21%),左侧壳核神经储备指数降低。
核心结论
- 在未用药PD患者中,合并糖尿病与临床严重度相当但多巴胺能丢失更轻相关,提示DM可能增加多巴胺系统脆弱性并降低黑质纹状体网络的效率与代偿机制。
研究设计与样本
- 研究分析两个独立PD患者队列:多中心PPMI队列n=174和单中心UniBS队列n=95。
- 患者按有无DM先比较,再按年龄、性别和临床严重度匹配。
- 所有患者接受基线123I-FP-CIT显像以量化多巴胺转运体结合。
- 比较严重度匹配组间的多巴胺能结合、神经储备指数和分子连接模式。
主要发现
- 合并DM的PD患者年龄更大、以男性为主,非运动和认知症状更差。
- 严重度匹配后,PD-DM较PD-n表现出更保留的黑质纹状体多巴胺摄取。
- PD-DM的黑质纹状体多巴胺能连接改变更少(10% vs 21%)。
- PD-DM左侧壳核神经储备指数降低,且仅在单中心队列中全纹状体神经储备指数降低。
临床怎么用
- 对未用药PD患者评估多巴胺转运体显像时,需考虑合并糖尿病可能使临床严重度与多巴胺能丢失程度不匹配。
- 合并糖尿病的PD患者即使多巴胺能丢失较轻,临床严重度可能相当,提示需关注代偿机制受损。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Diabetes Mellitus (DM) has been recognized as a potential risk factor and disease-modifier in Parkinson's Disease (PD), being associated with worse motor and cognitive outcomes, and altered susceptibility of neural pathways. This study investigated the impact of DM on nigrostriatal dopaminergic vulnerability independently of disease severity in drug-naïve PD patients. METHODS: This study analyzed two independent cohorts of PD patients (multi-center PPMI n = 174, single-center UniBS n = 95). Patients with and without DM were first compared and then matched for age, sex, and clinical severity. All patients underwent baseline 123I-FP-CIT imaging to quantify dopamine transporter binding. Dopaminergic binding, neural reserve index and molecular connectivity patterns were compared between severity-matched groups. RESULTS: Patients with DM were older, predominantly male, and exhibited worse non-motor and cognitive symptoms. After severity matching, PD-DM exhibited more preserved nigrostriatal dopamine uptake compared to PD-n. PD-DM also showed fewer nigrostriatal dopaminergic connectivity alterations (10% vs. 21%) and reduced neural reserve index in the left putamen and - only in the single-center cohort- whole striatum. CONCLUSION: In drug-naïve PD patients, comorbid diabetes is associated with comparable clinical severity despite milder dopaminergic loss. This suggests an increased dopamine system vulnerability linked to DM, reducing the efficiency and compensatory mechanisms of nigrostriatal dopaminergic networks in PD.
引用
- Galli A, Zatti C, Lupini A, et al. Dopaminergic nigrostriatal vulnerability in Parkinson's Disease with diabetes: evidence from severity-matched cohorts. Eur J Nucl Med Mol Imaging. 2026. PMID: 42321543. doi:10.1007/s00259-026-08011-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。